InicioFLNA • BMV
add
Filana Therapeutics Inc
Cierre anterior
30,76 $
Intervalo anual
30,00 $ - 56,00 $
Cap. bursátil
77,76 M USD
Volumen medio
13,00
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | dic 2025info | Cambio interanual |
|---|---|---|
Ingresos | — | — |
Gastos operativos | 5,70 M | -36,37 % |
Ingresos netos | -12,54 M | 54,56 % |
Margen de beneficio neto | — | — |
Beneficios por acción | — | — |
EBITDA | -9,18 M | 68,57 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | dic 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 95,50 M | -25,72 % |
Activos totales | 118,36 M | -24,87 % |
Responsabilidades totales | 43,95 M | 271,56 % |
Patrimonio total | 74,40 M | — |
Acciones en circulación | 48,31 M | — |
Precio-valor contable | 19,97 | — |
Rentabilidad económica | -19,25 % | — |
Retorno sobre capital | -30,62 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | dic 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | -12,54 M | 54,56 % |
Efectivo de operaciones | -9,75 M | 84,09 % |
Efectivo de inversión | -501,00 mil | -778,95 % |
Efectivo de financiación | -329,00 mil | -135,84 % |
Variación neta del flujo de caja | -10,58 M | 82,49 % |
Flujo de caja libre | -4,32 M | 64,46 % |
Información sobre la empresa
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
Fundación
1998
Empleados
19
